

1 **Identification of novel mitochondrial and mitochondrial related genetic loci**
2 **associated with exercise response in the Gene SMART study**

3 **NR Harvey**^{1,2}, S Voisin³, RA Lea², X Yan³, MC Benton², ID Papadimitriou³, M Jacques³, LM Haupt.², KJ
4 Ashton¹, N Eynon^{#3} and LR Griffiths^{#2}

5

6 ¹ Health Sciences and Medicine faculty, Bond University, Robina, QLD 4226

7 ² Genomics Research Centre, School of Biomedical Sciences, Institute of Health and Biomedical Innovation,
8 Queensland University of Technology, Brisbane, QLD 4059

9 ³ Institute for Health and Sport (IHES), Victoria University, Footscray, VIC 3011

10 **#Co-senior author: Lyn Griffiths and Nir Eynon**

11 ***Corresponding author:** Prof. Lyn R. Griffiths, Genomics Research Centre, Institute of Health and Biomedical
12 Innovation, Queensland University of Technology, Brisbane QLD, Australia

13 E-mail: lyn.griffiths@qut.edu.au

14

15 **NH:** 0000-0003-2035-8475, **SV:** 0000-0002-4074-7083, **XY:** 0000-0001-8547-4210, **MB:** 0000-0003-3442-
16 965X, **IP:** 0000-0001-5032-9937, **LH:** 0000-0002-7735-8110, **KA:** 0000-0001-6106-3425, **NE:** 0000-0003-
17 4046-8276, **LG:** 0000-0002-6774-5475

18

19 **ABSTRACT**

20 Mitochondria supply intracellular energy requirements during exercise. Specific mitochondrial haplogroups and
21 mitochondrial genetic variants have been associated with athletic performance, and exercise responses. However,
22 these associations were discovered using underpowered, candidate gene approaches, and consequently have not
23 been replicated. Here, we used whole-mitochondrial genome sequencing, in conjunction with high-throughput
24 genotyping arrays, to discover novel genetic variants associated with exercise responses in the Gene SMART
25 (Skeletal Muscle Adaptive Response to Training) cohort (n=62 completed). We performed a Principal Component
26 Analysis of cohort aerobic fitness measures to build composite traits and test for variants associated with exercise
27 outcomes. None of the mitochondrial genetic variants but nine nuclear encoded variants in eight separate genes
28 were found to be associated with exercise responses (FDR<0.05) (*rs11061368: DIABLO*, *rs113400963:*
29 *FAM185A*, *rs6062129* and *rs6121949: MTG2*, *rs7231304: AFG3L2*, *rs2041840: NDUFAF7*, *rs7085433:*
30 *TIMM23*, *rs1063271: SPTLC2*, *rs2275273: ALDH18A1*). Additionally, we outline potential mechanisms by
31 which these variants may be contributing to exercise phenotypes. Our data suggest novel nuclear-encoded SNPs
32 and mitochondrial pathways associated with exercise response phenotypes. Future studies should focus on
33 validating these variants across different cohorts and ethnicities.

34

35 **AUTHOR SUMMARY**

36 Previous exercise genetic studies contain many flaws that impede the growth in knowledge surrounding change
37 in exercise outcomes. In particular, exercise studies looking at mtDNA variants have looked at very small portions
38 of the mitochondrial genome. Mitochondria are the ‘power house’ of the cell and therefore understanding the
39 mitochondrial genetics behind adaptations to training can help us fill knowledge gaps in current research. Here,
40 we utilised a new mitochondrial genetic sequencing technique to examine all mitochondrial and mitochondrial
41 related genetic variations. We have shown that there were no mitochondrial specific variants that influenced
42 exercise training however there were 9 related variants that were significantly associated with exercise
43 phenotypes. Additionally, we have shown that building composite traits increased the significance of our
44 association testing and lead to novel findings. We will be able to understand why response to training is so varied
45 and increase the effectiveness of exercise training on a host of metabolic disorders.

46

47 **INTRODUCTION**

48 Responses to exercise training depends on the type of exercise stimulus, and varies considerably between
49 individuals (1-3). This variability is tissue-specific, and may be explained by a combination of genetic variants,
50 epigenetic signatures, other molecular and lifestyle factors (4, 5). Mitochondria are the key mediators of
51 intracellular energy and are involved in many essential cell metabolism and homeostasis processes (6) with
52 exercise training improving mitochondrial function and content (6-9).

53 The mitochondrial genome encodes 37 genes that are highly conserved but differ slightly amongst different
54 regional isolates (haplogroups) (10). Mitochondrial haplogroups and Single Nucleotide Polymorphisms (SNPs),
55 in conjunction with SNPs in mitochondrial-related genes (nuclear encoded mitochondrial proteins: NEMPs) have
56 previously been associated with athletic performance in highly trained populations and response to exercise
57 training in the general population (11). While these studies have advanced our understanding, they have primarily
58 utilised targeted genotyping technology such as candidate gene approaches, or Sanger sequencing to investigate
59 specific mitochondrial coding regions and NEMPs, such as *NRF2* and *PGC1 α* (12-15). Many of these studies also
60 lacked robust technical measures on aerobic fitness measures (9). As such, many of the identified variants have
61 not been replicated, and exercise-related genetic variants remain unknown (16).

62 To date, studies assessing mitochondrial DNA (mtDNA) variants and NEMPs pertaining to exercise training have
63 focused on protein-coding variants, with no studies looking at the more subtle effects of synonymous and non-
64 coding changes (11, 17-20). Further, these studies have often based haplogroup analyses on sequencing or
65 genotyping of the mitochondrial hypervariable region(s) (~500-1,000bp), with no consideration for the remaining
66 mitochondrial genome (~15,000bp) and the specific haplogroup of exercise participants. For instance, 3'UTR
67 (untranslated regions) variants that do not directly affect protein function may however affect translation, mRNA
68 shuttling to specific organelles, or epigenetic modification such as microRNA silencing (21). Intronic variants
69 may also lead to splice site changes directly contributing altered protein structure and function (22). As Next
70 Generation Sequencing has become more widely available and affordable, sequencing of the whole mitochondrial
71 genome (16,569 bp) is now feasible to uncover genetic variants associated with physical fitness phenotypes. When
72 used in combination with SNP genotyping arrays, it is possible to examine, not only the 37 mitochondrially-
73 encoded genes, but variants within all nuclear NEMP genes simultaneously.

74 Therefore, the aim of the present study was to examine the association between genetic variants (i.e. mitochondrial
75 variants and NEMPs), and aerobic fitness measures in the well-characterised Gene SMART cohort. We

76 hypothesise that by utilising whole-mitochondrial sequencing, we will uncover novel genetic variants associated
77 with exercise responses.

78 **RESULTS**

79 **Exercise responses and Principal Component Analysis (PCA)**

80 Participant characteristics and response to exercise for all phenotypes are detailed in **Table 1**. P-values shown for
81 delta variables are respective of one tail of a paired samples t-test.

82

83 **Table 1: Participant characteristics before and after four weeks of high-intensity interval training in the Gene SMART study**

| Phenotype (units) | Time point | Mean | SD | P-value |
|--------------------------------------|------------|---------|---------|----------------------|
| BMI (kg/m²) | PRE | 25.06 | ±3.20 | |
| | POST | 25.12 | ±3.27 | |
| | Δ | 0.04 | ±0.37 | 0.114 |
| Peak Power (Watts) | PRE | 296.88 | ±70.57 | |
| | POST | 315.84 | ±67.77 | |
| | Δ | 18.96 | ±16.49 | 2.28e ⁻¹³ |
| Lactate Threshold (Watts) | PRE | 209.22 | ±59.70 | |
| | POST | 224.91 | ±60.68 | |
| | Δ | 15.69 | ±16.24 | 7.47e ⁻¹¹ |
| VO_{2max} (mL/min·kg) | PRE | 46.34 | ±7.36 | |
| | POST | 47.46 | ±7.04 | |
| | Δ | 1.12 | ±3.84 | 0.012 |
| Time Trial (seconds) | PRE | 2295.99 | ±292.95 | |
| | POST | 2194.13 | ±246.91 | |
| | Δ | -101.86 | ±144.64 | 2.81e ⁻⁶ |

84 *Δ: Delta change, Min: Minimum value, Max: Maximum value, SD: Standard Deviation, VO_{2max}: maximal oxygen respiration metric,*

85 *Shading represents statistically significant delta changes*

86 Four weeks of HIIT elicited small yet significant improvements in Wpeak, LT, VO2max, and TT (PP: $18.96 \pm$
87 16.49 Watts, $P=2.28e^{-13}$; LT: 15.69 ± 16.24 Watts, $P=7.47e^{-11}$; VO2max: 1.12 ± 3.84 mL/min·kg, $P=0.012$; TT: -
88 101.86 ± 144.64 seconds, $P=2.81e^{-6}$).

89

90 There were 60 distinct haplogroups within the Gene SMART completed cohort of 62 participants. As such, there
91 were no statistically significant associations between the mitochondrial haplogroups with exercise response traits.

92 A summary table of the mitochondrial haplogroups found within the Gene SMART participants is shown in **Table**
93 **2**. The confidence scores (0-1) represent the number of mtDNA variants found in each participant that belong to
94 their respective haplogroup.

95

96 Following PCA on the response traits, we found that the first 4 principal components (PC1: 35.49%, PC2: 28.46%,
97 PC3: 16.51%, PC4: 12.74%) cumulatively explained 92.3% of the total variance between individuals; therefore
98 we included only these first 4 PCs in subsequent analyses.

99

100

101 **Table 2: Summary of mitochondrial Haplogroups within the Gene SMART study.**

| Participant ID | MtDNA Haplogroup | Confidence | Participant ID | MtDNA Haplogroup | Confidence |
|-----------------------|-------------------------|-------------------|-----------------------|-------------------------|-------------------|
| SG100 | H1c2a | 0.9505 | SG140 | H1c7 | 0.9581 |
| SG102 | C1b10 | 0.9305 | SG141 | H2a2b3 | 0.9386 |
| SG103 | K1a1b2b | 0.9648 | SG142 | H+152 | 0.8534 |
| SG104 | H6a1b2 | 0.9438 | SG143 | U4a1a | 1 |
| SG105 | H3g | 0.9353 | SG144 | T2b4+152 | 0.9535 |
| SG106 | H94 | 0.8164 | SG145 | H24a | 1 |
| SG107 | K1a1b1a | 0.968 | SG146 | U5b3e | 0.9818 |
| SG108 | J1c3g | 0.9366 | SG147 | U5a1a1 | 1 |
| SG109 | W3a1c | 0.9804 | SG148 | I1a1e | 0.9762 |
| SG110 | H1e1a3 | 0.9486 | SG149 | H6a1a3 | 0.9958 |
| SG111 | H1t | 0.9336 | SG150 | HV | 0.7231 |
| SG112 | K1a4f1 | 0.9641 | SG151 | U5a2b4 | 0.9481 |
| SG113 | T2b+152 | 0.9795 | SG152 | J1c2f | 0.9805 |
| SG114 | U5b1b1+@16192 | 0.9924 | SG153 | K1a4a1 | 0.9783 |
| SG115 | T2b13a | 0.9827 | SG154 | U2e1a1 | 0.94 |
| SG116 | J1c3g | 0.9639 | SG155 | H1a1 | 0.9505 |
| SG117 | H10 | 0.9356 | SG156 | H1a | 0.9898 |
| SG118 | H16b | 1 | SG157 | H3u1 | 0.8918 |
| SG119 | U3a1c1 | 0.9499 | SG158 | H1e1a2 | 0.9243 |
| SG120 | T2b1 | 0.9904 | SG159 | U4b1a2 | 0.9924 |
| SG121 | H15a1a1 | 0.9175 | SG160 | U8a1a | 0.9319 |
| SG122 | K1a | 0.9508 | SG161 | K1a | 0.9204 |
| SG123 | K1a4a1a+195 | 0.9941 | SG162 | U4b1a2 | 0.9924 |
| SG124 | H3 | 0.9852 | SG163 | H4a1a2a | 0.9818 |
| SG125 | L0d2a1a | 0.9839 | SG164 | H2a2b4 | 0.9037 |
| SG126 | H5a1 | 1 | SG165 | T2f1a1 | 0.9306 |
| SG127 | H2b | 0.8848 | SG166 | H1a1 | 1 |
| SG128 | H1 | 0.8676 | SG167 | U5a1b1d+1609 3 | 0.9791 |
| SG129 | H24a2 | 0.9202 | SG168 | H2a2a1 | 0.5 |
| SG130 | J2a1a1 | 0.9726 | SG169 | T2b | 0.9918 |
| SG131 | U8b1a1 | 0.9258 | SG170 | J1b1a1a | 0.9857 |
| SG132 | V10a | 0.9673 | SG171 | H6a1b3 | 0.985 |
| SG133 | HV1a1a | 0.9296 | SG172 | I2 | 0.9222 |
| SG134 | J1c7a | 0.9841 | SG173 | I2c | 0.9577 |
| SG135 | R1a1a2 | 0.9875 | SG174 | M1a | 0.905 |
| SG136 | HV6a | 0.951 | SG175 | W5 | 0.9513 |
| SG137 | H2a1e1a | 0.9591 | SG176 | T2f1a1 | 0.8887 |
| SG138 | H1b1+16362 | 1 | SG177 | K1a16 | 0.9932 |
| SG139 | J2b1a2a | 0.9655 | | | |

102 **Association between genetic variants (mitochondrial encoded and nuclear encoded) and exercise**
 103 **phenotypes**

104 Following quality control, 170 mitochondrial and 4,124 NEMP genetic variants were included in association
105 testing. A cumulative total of 4,325 NEMP variants and 28 mitochondrial variants passed the nominal threshold
106 of significance ($P_{\text{unadjusted}} < 0.05$) for all tests. A solar plot showing the clustering of mitochondrial genomic variants
107 for each trait is shown in **Fig 1** (23)(23)(33). The exonic variants passing the nominal threshold from the
108 mitochondrial association results are summarised in **Table 3**.

109

110

111 **Fig 1: Solar plot showing significant hits from mitochondrial association testing.** Each dot represents a
112 detected variant. The inner ring of the plot represents the mitochondrial genome and is coloured based on genomic
113 region as summarised in the plot legend. The X-axis represents the mitochondrial base pair location. The Y-axis
114 represents the significance level [-log₁₀ (P-value)] in the Gene SMART population over multiple traits. The
115 significance threshold was set at P<0.05 and is represented by the circular blue line. The concentric white rings
116 surrounding the genome represent the P-value thresholds -log₁₀ (0.01) and -log₁₀ (0.001) respectively.

117

118 **Table 3: Exonic mitochondrial SNPs associated with phenotypic traits and PCs.**

| Trait | CHR | SNP | Allele | Gene | Consequence | Model | MAF | SE (95% CI) | P-value* | FDR | Effect size (beta) |
|-------|-----|-------|--------|---------------------|-------------|-------|-------|----------------------|----------|------|--------------------|
| Δ-LT | MT | 8701 | G | ATP6 | Missense | ADD | 0.032 | 11.24 (-48.2 - -4.2) | 0.023 | 0.39 | -26.19 |
| | MT | 10873 | C | ND4 | Synonymous | ADD | 0.032 | 11.24 (-48.2 - -4.2) | 0.023 | 0.39 | -26.19 |
| | MT | 12705 | T | ND5 | Synonymous | ADD | 0.081 | 7.25 (-29 - -0.5) | 0.046 | 0.49 | -14.75 |
| | MT | 15043 | A | CYB | Synonymous | ADD | 0.113 | 6.08 (-29 - -5.2) | 0.0067 | 0.28 | -17.10 |
| PC3 | MT | 10873 | C | ND4 | Synonymous | ADD | 0.032 | 0.72 (0.17 - 3.0) | 0.032 | 0.54 | 1.57 |
| | MT | 8701 | G | ATP6 | Missense | ADD | 0.032 | 0.72 (0.17 - 3.0) | 0.032 | 0.54 | 1.57 |
| PC4 | MT | 11467 | G | ND4 | Synonymous | ADD | 0.258 | 0.25 (-1.0 - -0.03) | 0.041 | 0.69 | -0.53 |
| | MT | 12308 | G | tRNA ^{Leu} | - | ADD | 0.258 | 0.25 (-1.0 - -0.03) | 0.041 | 0.69 | -0.53 |
| | MT | 12372 | A | ND5 | Synonymous | ADD | 0.258 | 0.25 (-1.0 - -0.03) | 0.041 | 0.69 | -0.53 |

119 *CHR: Chromosome #, SNP: Single Nucleotide Polymorphism, MAF: Minor Allele Frequency, SE: Standard Error, CI: Confidence Interval, FDR = False Discovery Rate, Δ:*
120 *delta change, ADD: Additive model*

121 **P-value adjusted for age*

122

123

124 28 variants passed the nominal significance threshold of $P_{\text{unadjusted}} < 0.05$ in various delta traits and principal
125 components. Of these, 8 were located within the hypervariable control region and therefore discounted from
126 further analyses. A further 2 genetic variants were located within a mitochondrial rRNA gene, 1 within the *tRNA^{Leu}*
127 gene, 1 within the *mitochondrially encoded ATP synthase membrane subunit 6 (ATP6)* gene, 2 within the
128 *mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 4 (ND4)*, 2 in *mitochondrially encoded*
129 *NADH: ubiquinone oxidoreductase core subunit 5 (ND5)* and 1 in mitochondrially encoded cytochrome B (*CYB*).
130 None of the mitochondrial genomic variants were associated with composite response traits or individual response
131 traits at $FDR < 0.05$. A manhattan plot of the NEMP variants is shown in **Figure 2**. A summary of the association
132 statistics for the variants passing a nominal threshold of $P_{\text{unadjusted}} < 1e^{-4}$ in both the NEMP associations are shown
133 in **Table 4**.

134

135

136 **Fig 2: Manhattan plot for all hits from all response phenotypes, biochemical measures, and PCs in the linear dominant and recessive association models.** Suggestive
137 significance was set at $-\log_{10}(P_{\text{unadjusted}} = 0.0001)$, blue line). As all traits were included clusters of variants represent association across multiple traits rather than one
138 significant locus commonly associated with GWAS.

139

140

141 **Table 4: Summary statistics for exonic variants in the nuclear encoded, mitochondria-related genes**

| Trait | CHR | SNP | Response Allele | Gene | Consequence | Model | MAF | Effect size (beta) | SE (95% CI) | P-value* | FDR |
|------------------------------|-----|-------------|-----------------|---------|----------------------|-------|-------|--------------------|----------------------|----------|--------------|
| Δ -LT | 18 | rs12964779 | A | RBFA | Intronic | DOM | 0.49 | -16.67 | 3.94 (-24.4 - -8.9) | 8.25E-05 | 0.288 |
| | 7 | rs113400963 | G | FAM185A | Intronic | REC | 0.096 | 587.7 | 127.2 (338.5 - 837) | 2.23E-05 | 0.013 |
| | 10 | rs7085433 | T | TIMM23 | Noncoding transcript | REC | 0.096 | 587.7 | 127.2 (338.5 - 837) | 2.23E-05 | 0.013 |
| Δ -TT | 12 | rs11061368 | G | DIABLO | Intronic | REC | 0.088 | 587.7 | 127.2(338.5 - 837) | 2.23E-05 | 0.013 |
| | 14 | rs1063271 | C | SPTLC2 | 3`UTR | REC | 0.16 | 587.7 | 127.2(338.5 - 837) | 2.23E-05 | 0.013 |
| | 20 | rs6062129 | C | MTG2 | Intronic | REC | 0.29 | 587.7 | 127.2 (338.5 - 837) | 2.23E-05 | 0.013 |
| | 20 | rs6121949 | G | MTG2 | Intronic | REC | 0.14 | 587.7 | 127.2 (338.5 - 837) | 2.23E-05 | 0.013 |
| Δ -VO _{2max} | 2 | rs2041840 | T | NDUFAF7 | Intronic | DOM | 0.48 | 4.257 | 0.965 (-7.6 - -3.1) | 4.52E-05 | 0.184 |
| | 7 | rs322820 | T | SND1 | Intronic | REC | 0.36 | -5.346 | 1.168 (2.4 - 6.1) | 2.54E-05 | 0.091 |
| Δ -PP | 2 | rs2041840 | T | NDUFAF7 | Intronic | DOM | 0.48 | 17.3 | 4.066 (9.3 - 25.3) | 7.56E-05 | 0.173 |
| | 2 | rs2041840 | T | NDUFAF7 | Intronic | DOM | 0.48 | 1.737 | 0.309 (1.1 - 2.3) | 5.45E-07 | 0.002 |
| PC2 | 9 | rs4742213 | T | GLDC | Intronic | REC | 0.45 | -1.471 | 0.3517 (-0.9 - -4.7) | 9.73E-05 | 0.348 |
| | 18 | rs7231304 | C | AFG3L2 | Intronic | DOM | 0.14 | -1.564 | 0.3298 (-0.8 - -4.2) | 1.38E-05 | 0.028 |

142 *CHR: Chromosome #, SNP: Single Nucleotide Polymorphism, MAF: Minor Allele Frequency, SE: Standard Error, CI: Confidence Interval, FDR = False Discovery Rate, Δ :*

143 *delta change, DOM: Dominant model, REC: Recessive model*

144 **P-value adjusted for age*

146 A full list of variants reaching the nominal P value threshold (<0.05) may be found in (**Supplementary Table**
147 **SI**). 6 SNPs in 5 distinct genes were associated with Δ TT and 2 SNPs in 2 distinct genes were associated with
148 PC2. The most significant variant was rs2041840 associated with PC2 and located within *NDUFAF7*; we found
149 that the rs12712528 variant also within *NDUFAF7* had a moderate correlation with rs2041840 ($R^2=0.5$) **Figure**
150 **3a**. This variant was also trending towards significance in the Δ -Weight and Δ -VO_{2max} response phenotypes (**Table**
151 **3**). The T allele at rs2041840 was associated with a better response to exercise. The Locus Zoom plot (**Fig 3b**)
152 surrounding the *MTG2* gene was also gene-rich with 11 proximal genes. The two associated variants (rs6062129
153 and rs6121949) were moderately correlated ($R^2=0.5$), however there were no SNPs found within the proximal
154 genes. The locus zoom plot for the variants found within the *AFG3L2* gene (**Fig 3c**) was proximal to 6 genes
155 within 200Kb. There was also a proximal SNP within the *SLMO1* gene however this was not in linkage with the
156 variants identified within the *AFG3L2* gene.

157

158

159

160

161

162 **Fig 3 Locus Zoom plots of significant intronic SNPs from the nuclear mitochondrial association testing.** Each panel shows the locus surrounding a) rs2041840 within
163 the NDUFAF7 gene, b) rs6062129 variant within the MTG2 gene, and c) rs7231304 variant within the AFG3L2 gene. All panels show the gene of interest ± 200 Kb. Left y-
164 axis shows $-\log_{10}(\text{p-value})$ of association results for all traits and right y-axis shows recombination rate across the locus in relation to the variant of interest. X-axis shows
165 genomic position across the respective chromosomal regions.

166

167

168 **DISCUSSION**

169 In this study, we utilised state-of-the-art mitochondrial sequencing, along with high-throughput targeted
170 genotyping of mitochondrial-related variants encoded by the nucleus (NEMPs) to discover novel genetic variants
171 associated with responses to exercise. A total of 28 mitochondrial and 4,325 nuclear encoded mitochondrial
172 associated variants passed the nominal significance thresholds for the various candidate gene association tests.
173 We did not detect mitochondrial variants associated with exercise response, but we uncovered eight NEMPs in
174 seven distinct genes associated with exercise response.

175 **Novel exercise loci**

176 The most significant variant was associated with the composite exercise response phenotype and located within
177 an intron of *NDUFAF7* (rs2041840). The T allele was associated with better exercise response as shown by the
178 positive beta values. *NDUFAF7* encodes an arginine methyltransferase that is essential for mitochondrial complex
179 I assembly (24). We have showed that this variant was in a gene rich region with 8 proximal genes (**Fig 3a**),
180 indicating possible effects for this variant in any of the proximal genes or indeed for genes that may be further
181 away from the loci.

182 The two intronic variants within the *MTG2* gene were found to be associated with the change in time trial measures
183 and appeared to be moderately linked (**Figure 3b**). The *MTG2* gene resides in a gene rich locus with 11 proximal
184 genes. The MTG protein regulates the assembly and function of the mitochondrial ribosome. As such,
185 dysregulation of the gene could result in the downregulation of mitochondrial transcription, and therefore a lower
186 response to exercise training. The variants also showed a 20% recombination rate with the 5' region of the *TAF4*
187 gene. The TAF4 protein forms part of the transcription factor II D (TFIID) complex and has a central role in
188 mediating promoter responses to transcriptional activators and repressors. Dysregulation of this gene could
189 introduce global translational repression and therefore lack of response to HIIT training. This is supported by the
190 positive effect size for the C and G alleles of the *MTG2* variants rs6062129 and rs6121949 respectively ($\beta = 587.7$
191 seconds).

192 An intronic variant within *AFG3L2* was also shown to be associated with the composite exercise response
193 phenotype (rs7231304), but this gene has not previously been associated with exercise response. However,
194 mutations in *AFG3L2* have been shown to cause spinocerebellar ataxia through the development of mitochondrial
195 proteotoxicity (25, 26). As such, the intronic variation within this gene might inhibit exercise response through
196 dysregulation of mitochondrial structure and function. Further, this variant is in a locus with 6 proximal genes

197 **(Fig 3c)**, however no genes within this locus shared a recombination rate above 10%. There were two proximal
198 SNPs with a moderate correlation to the SNP of interest also within the *AFG3L2* genic region.

199 The T allele at the exonic rs7085433 variant in the *TIMM23* gene was associated with the change in time trial
200 phenotype (Δ -TT) causes a non-coding transcript of the *TIMM23* gene. This gene is one of the targets of
201 transcriptional activators NRF-1 and GA binding protein (GABP/NRF-2) (27), in which we have previously
202 shown genetic variants associated with athletic performance (28, 29). *TIMM23* is one of the mitochondrial
203 transmembrane subunits that form the mitochondrial protein import (TIM23) complex. Therefore, this subunit is
204 essential for the transport of peptide containing proteins across the inner mitochondrial membrane. The non-
205 coding transcript resulting from the variant would render the complex non-functional and as such impaired
206 transport of biomolecules across the inner mitochondrial membrane may impair exercise potential. The effect size
207 of this variant was very highly positive ($\beta = 587.7$ seconds) and therefore, this non-coding transcript may result
208 in a slower time to complete the time trial.

209 The rs1063271 variant lies within the 3' Untranslated Region (UTR) of the *SPTLC2* gene. UTR variants have
210 been shown to influence transcript half-life; through the dysregulated binding of transcript shuttle proteins; or
211 change the binding site of miRNAs resulting in epigenetic silencing of the gene (30). The *SPTLC2* protein is
212 involved in the de novo biosynthesis of sphingolipids by forming a complex with its counterpart; *SPTLC1* (31).
213 Overexpression of this protein has also been shown to cause elevated sphingolipid formation and therefore
214 mitochondrial autophagy (32). Much like the *TIMM23* rs7085433 variant, the effect size for time to completion
215 in Time Trial ($\beta = 587.7$ seconds) indicated that carriers of T allele/genotype have slower TT and therefore poorer
216 response to exercise when compared to carriers of the C allele/genotype. We hypothesise that the C allele for this
217 variant may induce a novel miRNA binding site in the transcript resulting in the silencing of the *SPTLC2* gene.

218 The rs11061368 variant lies within an intronic region of the *DIABLO* gene. The protein encoded by this gene
219 functions to induce apoptotic processes through the activation of caspases in the Cytochrome C/Apaf-1/caspase-
220 9 pathway. We hypothesise that the dysregulation of the *DIABLO* gene could prevent adequate muscle
221 remodelling resulting in the lack of response to training. The variant also lies ~50Kb away from the *Interleukin*
222 *31* (*IL31*) gene, a pro-inflammatory cytokine associated with the activation of Signal Transducer and Activator of
223 Transcription 3 (STAT3) pathways.

224 **Mitochondrial**

225 None of the mitochondrial genetic variants identified in this study were associated with exercise response in the
226 present study to a threshold of $FDR < 0.05$. Additionally, we lacked enough statistical power to associate
227 mitochondrial haplogroup with exercise responses as the cohort was extremely heterogenous.

228 The g.A8701G variant within the *ATP6* gene causes a missense change within its respective protein (p.Thr59Ala)
229 and has been well characterised in hypertensive cases (33). This variant was nominally significant in both the Δ -
230 LT phenotype and the PC3 composite trait within the cohort. As the Δ -LT trait provides a smaller contribution
231 to PC3, the variant was assumed to be partially associated with a mixture of the Δ -TT and Δ -VO_{2max} phenotypes.
232 The effect size of this variant indicated a poor response to exercise training ($\beta = -26.19$ LT).

233 Interestingly, all the variants associated with PC4 were related to the utilisation of the amino acid Leucine. Firstly,
234 the g.A12308G variant within the mitochondrial coding region for the tRNA for Leucine. Whilst the effect of this
235 variant was unclear, it appears to have influenced the composite phenotypes within PC4. Mutations within tRNA
236 genes have previously been associated with reduction in organelle quantity and downregulation of protein
237 synthesis (34). Secondly, both synonymous variants in the ND4 (g.A11467G) and ND5 (g.G12372A) genes result
238 in a codon that is used far less frequently ($CUA_{[276]} > CUG_{[42]}$) in mitochondrial translation processes (35). As the
239 biosynthesis of tRNAs is costly with respect to intracellular energy levels, it is possible that the combination of
240 the dysregulation of the tRNA^{leu} and the codon usage frequency change in two subunits of the mitochondrial
241 membrane respiratory chain NADH dehydrogenase (complex I) may result in premature intracellular energy
242 (ATP) deficiency and contribute to the poor response to exercise training associated with these traits. It should be
243 noted that the stringent thresholds for association in the mitochondrial association tests could also have resulted
244 in false negative results. Additionally, mitochondrial genetic variants rarely influence phenotypic traits in
245 isolation.

246 We have identified novel nuclear-encoded, mitochondrial-related SNPs and loci associated with adaptations to
247 High Intensity Interval Training. Additionally, we have postulated the mode of action for different molecular
248 mechanisms that may be responsible for the variability in response to exercise intervention. It should be noted
249 that performing mitochondrial sequencing on muscle tissue as opposed to blood may yield more informative
250 results with heteroplasmic associations due to the high concentration of mitochondria. We note that while we have
251 utilised comprehensive sequencing and high throughput arrays in combination with robust exercise phenotypes,
252 the variants associated with responses in this study, need to be replicated in larger cohorts of both the general
253 population and elite athletes. This could be achieved by leveraging on large multi-centre initiatives such as the

254 Athlome consortium (36). Additionally, functional genomic analyses are required to determine the effect of these
255 variants on the molecular pathways commonly involved in exercise response. Such studies could include
256 transcriptomics, epigenetics and functional cell work in a multi-omics approach.

257

258 **MATERIALS AND METHODS**

259 **Participants**

260 At the time of analysis, 77 participants had taken part in the study, 62 of whom successfully completed 4 weeks
261 of High-Intensity Interval Training (HIIT) intervention protocol in the Gene SMART (Skeletal Muscle Adaptive
262 Response to Training) study (37) at Victoria University, Australia. Ethical clearance for this study was provided
263 by the Human Research Ethics Committee at Victoria University (Approval Number: HRE13-233), and the
264 clearance was transferred to and also provided by the QUT Human Research Ethics Committee (Approval
265 Number: 1600000342). We analysed the 62 participants who did not drop out of the study and all had healthy
266 BMI and were moderately trained with an age range of (31.33 ± 7.94 years).

267 The Gene SMART study design has been previously reported (37). Briefly, participants were required to provide
268 medical clearance to satisfy the inclusion criteria. Following familiarisation, baseline exercise performance was
269 determined on a cycle ergometer during a 20 km time trial (TT), and two graded exercise tests (GXTs); these tests
270 were administered a few days apart and no more than two weeks apart to limit temporal variability in performance.

271 **Molecular Methods**

272 Genomic DNA was extracted for 77 participants regardless of completion status from 2.0mL of whole blood using
273 a QIAmp DNA blood midi kit (QIAGEN, Hilden, Germany). Briefly, the concentration and purity of genomic
274 DNA (gDNA) from all samples was assessed via Nanodrop spectrophotometry and Qubit fluorometry. We used
275 an in-house sequencing method recently developed by our group at the Genomics Research Centre, Queensland
276 University of Technology, Australia to sequence the whole mitochondrial genome of each participant (38).
277 Illumina Infinium Microarray was used on HumanCoreExome-24v1.1 bead chip to genotype all samples for
278 ~550,000 loci. For all samples, 1 μ g total gDNA was sent to the Australian Translational Genomics Centre,
279 Queensland University of Technology Australia, for SNP genotyping on the arrays.

280 **Data Filtering**

281 A bioinformatics pipeline (*SAMtools*, *BCFtools*) was utilised to generate variant call files (VCF) for all samples
282 as described previously (38). VCF files were then aligned to the *revised Cambridge Reference Sequence* (rCRS)
283 and all sequences were stringently left aligned back to this reference genome to account for the single end (SE)
284 reads generated from Ion Torrent sequence information. FASTA files were generated for all samples and then
285 merged VCF and FASTA files were produced for the entire data set. The merged FASTA files were annexed
286 using MITOMASTER, a mitochondrial sequence database, to call haplogroups and obtain variant annotation
287 information for all samples (39)(25). The merged VCF file was converted to PLINK (v1.90p) format using the
288 function ‘*--make-bed*’ for further association analysis.

289 The *ped* file generated from Illumina GenomeStudio v2.0 software was converted into binary format. We did not
290 impute any genotypes to prevent false positive associations and a larger multiple testing burden. There were
291 551,839 typed SNPs; subsequent SNP and individual filtering and trimming was based on **1**) SNPs with > 20%
292 missing data (239 removed), **2**) individuals with > 20% missing data (0 removed), **3**) minor allele frequency <
293 0.01 to remove rare variant associations (260,269 removed), **4**) SNPs out of Hardy Weinberg equilibrium for
294 quantitative traits (58 removed due to $P < 1e^{-6}$) (40). All samples passed kinship and heterozygosity thresholds after
295 the filtering outlined above, leaving 62 samples and 291,273 SNPs to analyse. A BED file containing the genomic
296 locations (GRCh37) of all known Nuclear Encoded Mitochondrial Protein genes (NEMPs) was obtained from the
297 Broad Institute’s human MitoCarta2.0 website (41-44). PLINK was used to extract the SNPs within the genomic
298 locations from the Omni Express SNP chip data of the same participants. In total, 4,806 SNPs were within the
299 NEMP genomic regions detailed by the Broad Institute MitoCarta2.0 bed file and considered to be mitochondrially
300 related variants.

301 **Exercise-response phenotypes**

302 Participant stratification into high and low response groups lead to a loss of statistical power in association testing.
303 As such, and to avoid classifying responders and non-responders via arbitrary thresholds, we chose to keep the
304 phenotypes as continuous variables for association testing (45).

305 To ascertain variants that were associated with exercise response for key physiological traits, we utilised the delta
306 (Δ) change (Post phenotype – Pre phenotype) quantitative trait data for; peak power output (ΔW_{peak} in Watts);
307 power at lactate threshold (ΔLT in Watts); peak oxygen uptake ($\Delta VO_{2\text{peak}}$ in mL/min/kg body weight); and time
308 to completion measurement for a 20 km time trial (ΔTT in seconds). As the quantitative traits were all continuous
309 and to keep maximal statistical power, we did not use arbitrary response thresholds. With multiple, correlated

310 response phenotypes, we conducted a Principal Component Analysis (PCA) of the response phenotypes using the
311 R package *FactoMineR* (46). PCA is a dimensionality reduction method that computes linear combinations of the
312 multiple response phenotypes into principal components (PCs) so that the variance between individuals is
313 maximised. Every individual is then represented by one value for each PC, considered a composite trait of the
314 different response phenotypes. A more detailed description of PCA for composite trait association testing is shown
315 in **Supplementary Fig 1**.

316 Missing phenotypic values were excluded from the phenotype table prior to PCA to prevent skewing of data and
317 to maintain appropriate PCs. Following the PCA, these variables were set as “missing” for the association analysis.
318 We also tested the individual response phenotypes and compared the significance levels of variants between the
319 composite traits with those within each PC. This resulted in 4 PCs that cumulatively explained > 90% of the
320 variance between participants.

321 **Statistical analysis**

322 Analysis of the response traits was performed in SPSS using a paired samples t-test. SPSS was also used to test
323 associations between mitochondrial haplogroups and exercise response with a Wald test. Analyses for the
324 mitochondrial SNPs and NEMP SNPs were kept separate for analysis using different association models. We used
325 PLINK V1.90p to perform quantitative linear association tests (95% CI) with both dominant and recessive models.
326 An additive model was also attempted but yielded the same results as our dominant model. We adjusted all
327 association results for age and effect sizes were determined using raw beta regression coefficient values (i.e.
328 genotype X is associated with β [unit specific to trait of interest] changes in the phenotype). Variants that passed
329 a nominal P value threshold of $P < 0.05$ were considered for further analysis whereas variants that passed multiple
330 testing adjustment using the Benjamini-Hochberg False Discovery Rate ($FDR < 0.05$) method were considered
331 significant associations. We performed adjustment for multiple testing for each phenotype separately. All variants
332 from the association tests were plotted in R using the *tidyverse*, *ggplot2*, and *qqman* packages.

333

334

335 **Acknowledgements**

336 This research was supported by Commonwealth Collaborative Research Network funding to Bond University
337 CRN-AESS. Mr Nicholas Harvey was supported by a PhD stipend also provided by Bond University CRN-AESS.

338 This research was also supported by infrastructure purchased with Australian Government EIF Super Science
339 Funds as part of the Therapeutic Innovation Australia - Queensland Node project (LRG). Nir Eynon is supported
340 by the National Health and Medical Research Council (NHMRC), Australia (NHMRC CDF# APP1140644).
341 Sarah Voisin is also supported by the NHMRC (ECF# APP1157732) and by the Jack Brockhoff foundation.

342

343

344 **COMPETING INTERESTS**

345 The authors declare that they have no conflicts of interest.

346

347 **REFERENCES**

- 348 1. Bouchard C, Rankinen T. Individual differences in response to regular physical activity. *Med*
349 *Sci Sports Exerc.* 2001;33(6 Suppl):S446-51; discussion S52-3.
- 350 2. Vellers HL, Kleeberger SR, Lightfoot JT. Inter-individual variation in adaptations to endurance
351 and resistance exercise training: genetic approaches towards understanding a complex phenotype.
352 *Mamm Genome.* 2018;29(1-2):48-62.
- 353 3. Bishop DJ, Botella J, Genders AJ, Lee MJ, Saner NJ, Kuang J, et al. High-Intensity Exercise and
354 Mitochondrial Biogenesis: Current Controversies and Future Research Directions. *Physiology*
355 (Bethesda). 2019;34(1):56-70.
- 356 4. Williams CJ, Williams MG, Eynon N, Ashton KJ, Little JP, Wisloff U, et al. Genes to predict
357 VO₂max trainability: a systematic review. *BMC Genomics.* 2017;18(Suppl 8):831.
- 358 5. Jacques M, Hiam D, Craig J, Barres R, Eynon N, Voisin S. Epigenetic changes in healthy human
359 skeletal muscle following exercise- a systematic review. *Epigenetics.* 2019;14(7):633-48.
- 360 6. Hood DA, Memme JM, Oliveira AN, Triolo M. Maintenance of Skeletal Muscle Mitochondria
361 in Health, Exercise, and Aging. *Annu Rev Physiol.* 2018.
- 362 7. Wyckelsma VL, Levinger I, McKenna MJ, Formosa LE, Ryan MT, Petersen AC, et al. Preservation
363 of skeletal muscle mitochondrial content in older adults: relationship between mitochondria, fibre
364 type and high-intensity exercise training. *J Physiol.* 2017;595(11):3345-59.
- 365 8. Seo DY, Lee SR, Kim N, Ko KS, Rhee BD, Han J. Age-related changes in skeletal muscle
366 mitochondria: the role of exercise. *Integr Med Res.* 2016;5(3):182-6.
- 367 9. Bishop DJ, Granata C, Eynon N. Can we optimise the exercise training prescription to maximise
368 improvements in mitochondria function and content? *Biochim Biophys Acta.* 2014;1840(4):1266-75.
- 369 10. Nicholls TJ, Gustafsson CM. Separating and Segregating the Human Mitochondrial Genome.
370 *Trends Biochem Sci.* 2018;43(11):869-81.
- 371 11. Eynon N, Moran M, Birk R, Lucia A. The champions' mitochondria: is it genetically determined?
372 A review on mitochondrial DNA and elite athletic performance. *Physiol Genomics.* 2011;43(13):789-
373 98.
- 374 12. Shockett PE, Khanal J, Sitaula A, Oglesby C, Meachum WA, Castracane VD, et al. Plasma cell-
375 free mitochondrial DNA declines in response to prolonged moderate aerobic exercise. *Physiol Rep.*
376 2016;4(1).
- 377 13. McCann BJ, Tuppen HA, Kusters B, Lammens M, Smeitink JA, Taylor RW, et al. A novel
378 mitochondrial DNA m.7507A>G mutation is only pathogenic at high levels of heteroplasmy.
379 *Neuromuscul Disord.* 2015;25(3):262-7.
- 380 14. Grady JP, Murphy JL, Blakely EL, Haller RG, Taylor RW, Turnbull DM, et al. Accurate
381 measurement of mitochondrial DNA deletion level and copy number differences in human skeletal
382 muscle. *PLoS One.* 2014;9(12):e114462.
- 383 15. Spendiff S, Reza M, Murphy JL, Gorman G, Blakely EL, Taylor RW, et al. Mitochondrial DNA
384 deletions in muscle satellite cells: implications for therapies. *Hum Mol Genet.* 2013;22(23):4739-47.
- 385 16. Vlahovich N, Hughes DC, Griffiths LR, Wang G, Pitsiladis YP, Pigozzi F, et al. Genetic testing for
386 exercise prescription and injury prevention: AIS-Athlome consortium-FIMS joint statement. *BMC*
387 *Genomics.* 2017;18(Suppl 8):818.
- 388 17. Martinez-Redondo D, Marcuello A, Casajus JA, Ara I, Dahmani Y, Montoya J, et al. Human
389 mitochondrial haplogroup H: the highest VO₂max consumer--is it a paradox? *Mitochondrion.*
390 2010;10(2):102-7.
- 391 18. Marcuello A, Martinez-Redondo D, Dahmani Y, Casajus JA, Ruiz-Pesini E, Montoya J, et al.
392 Human mitochondrial variants influence on oxygen consumption. *Mitochondrion.* 2009;9(1):27-30.
- 393 19. Dumoulin R, Sagnol I, Ferlin T, Bozon D, Stepien G, Mousson B. A novel gly290asp
394 mitochondrial cytochrome b mutation linked to a complex III deficiency in progressive exercise
395 intolerance. *Mol Cell Probes.* 1996;10(5):389-91.

- 396 20. Dionne FT, Turcotte L, Thibault MC, Boulay MR, Skinner JS, Bouchard C. Mitochondrial DNA
397 sequence polymorphism, VO₂max, and response to endurance training. *Med Sci Sports Exerc.*
398 1993;25(7):766-74.
- 399 21. Zhang F, Lupski JR. Non-coding genetic variants in human disease. *Hum Mol Genet.*
400 2015;24(R1):R102-10.
- 401 22. Cooper DN. Functional intronic polymorphisms: Buried treasure awaiting discovery within our
402 genes. *Hum Genomics.* 2010;4(5):284-8.
- 403 23. Mitochondrial Solarplot [Internet]. [cited 30 Jan 2019]. Available from:
404 <https://github.com/stephenturner/solarplot>
- 405 24. Zurita Rendon O, Silva Neiva L, Sasarman F, Shoubridge EA. The arginine methyltransferase
406 NDUFAF7 is essential for complex I assembly and early vertebrate embryogenesis. *Hum Mol Genet.*
407 2014;23(19):5159-70.
- 408 25. Cesnekova J, Rodinova M, Hansikova H, Zeman J, Stiburek L. Loss of Mitochondrial AAA
409 Proteases AFG3L2 and YME1L Impairs Mitochondrial Structure and Respiratory Chain Biogenesis. *Int J*
410 *Mol Sci.* 2018;19(12).
- 411 26. Mancini C, Hoxha E, Iommarini L, Brussino A, Richter U, Montarolo F, et al. Mice harbouring a
412 SCA28 patient mutation in AFG3L2 develop late-onset ataxia associated with enhanced mitochondrial
413 proteotoxicity. *Neurobiol Dis.* 2019;124:14-28.
- 414 27. Prieto-Ruiz JA, Alis R, Garcia-Benlloch S, Saez-Atienzar S, Ventura I, Hernandez-Andreu JM, et
415 al. Expression of the human TIMM23 and TIMM23B genes is regulated by the GABP transcription
416 factor. *Biochim Biophys Acta Gene Regul Mech.* 2018;1861(2):80-94.
- 417 28. Eynon N, Ruiz JR, Bishop DJ, Santiago C, Gomez-Gallego F, Lucia A, et al. The rs12594956
418 polymorphism in the NRF-2 gene is associated with top-level Spanish athlete's performance status. *J*
419 *Sci Med Sport.* 2013;16(2):135-9.
- 420 29. Eynon N, Ruiz JR, Meckel Y, Moran M, Lucia A. Mitochondrial biogenesis related endurance
421 genotype score and sports performance in athletes. *Mitochondrion.* 2011;11(1):64-9.
- 422 30. Steri M, Idda ML, Whalen MB, Orru V. Genetic variants in mRNA untranslated regions. *Wiley*
423 *Interdiscip Rev RNA.* 2018;9(4):e1474.
- 424 31. Han G, Gupta SD, Gable K, Niranjana Kumari S, Moitra P, Eichler F, et al. Identification of small
425 subunits of mammalian serine palmitoyltransferase that confer distinct acyl-CoA substrate
426 specificities. *Proc Natl Acad Sci U S A.* 2009;106(20):8186-91.
- 427 32. Alexaki A, Gupta SD, Majumder S, Kono M, Tuymetova G, Harmon JM, et al. Autophagy
428 regulates sphingolipid levels in the liver. *J Lipid Res.* 2014;55(12):2521-31.
- 429 33. Zhu Y, Gu X, Xu C. Mitochondrial DNA 7908-8816 region mutations in maternally inherited
430 essential hypertensive subjects in China. *BMC Med Genomics.* 2018;11(1):89.
- 431 34. Moraes CT, Ciacci F, Bonilla E, Jansen C, Hirano M, Rao N, et al. Two novel pathogenic
432 mitochondrial DNA mutations affecting organelle number and protein synthesis. Is the
433 tRNA(Leu(UUR)) gene an etiologic hot spot? *J Clin Invest.* 1993;92(6):2906-15.
- 434 35. Jia W, Higgs PG. Codon usage in mitochondrial genomes: distinguishing context-dependent
435 mutation from translational selection. *Mol Biol Evol.* 2008;25(2):339-51.
- 436 36. Pitsiladis YP, Tanaka M, Eynon N, Bouchard C, North KN, Williams AG, et al. Athlome Project
437 Consortium: a concerted effort to discover genomic and other "omic" markers of athletic
438 performance. *Physiol Genomics.* 2016;48(3):183-90.
- 439 37. Yan X, Eynon N, Papadimitriou ID, Kuang J, Munson F, Tirosh O, et al. The gene SMART study:
440 method, study design, and preliminary findings. *BMC Genomics.* 2017;18(Suppl 8):821.
- 441 38. Harvey NR, Albury CL, Stuart S, Benton MC, Eccles DA, Connell JR, et al. Ion torrent high
442 throughput mitochondrial genome sequencing (HTMGS). *PLoS One.* 2019;14(11):e0224847.
- 443 39. Mitomaster online database [Internet]. [cited 30 Jan 2019]. Available from:
444 <https://www.mitomap.org/foswiki/bin/view/MITOMASTER/WebHome>.

- 445 40. Marees AT, de Kluiver H, Stringer S, Vorspan F, Curis E, Marie-Claire C, et al. A tutorial on
446 conducting genome-wide association studies: Quality control and statistical analysis. *Int J Methods*
447 *Psychiatr Res.* 2018;27(2):e1608.
- 448 41. Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: an updated inventory of mammalian
449 mitochondrial proteins. *Nucleic Acids Res.* 2016;44(D1):D1251-7.
- 450 42. Falk MJ, Pierce EA, Consugar M, Xie MH, Guadalupe M, Hardy O, et al. Mitochondrial disease
451 genetic diagnostics: optimized whole-exome analysis for all MitoCarta nuclear genes and the
452 mitochondrial genome. *Discov Med.* 2012;14(79):389-99.
- 453 43. Stuart S, Benton MC, Eccles DA, Sutherland HG, Haupt LM, Lea RA, et al. Gene-centric analysis
454 implicates nuclear encoded mitochondrial protein gene variants in migraine susceptibility. *Mol Genet*
455 *Genomic Med.* 2017;5(2):157-63.
- 456 44. Pagliarini DJ, Calvo SE, Chang B, Sheth SA, Vafai SB, Ong SE, et al. A mitochondrial protein
457 compendium elucidates complex I disease biology. *Cell.* 2008;134(1):112-23.
- 458 45. Voisin S, Jacques M, Lucia A, Bishop DJ, Eynon N. Statistical Considerations for Exercise
459 Protocols Aimed at Measuring Trainability. *Exerc Sport Sci Rev.* 2019;47(1):37-45.
- 460 46. Lê S, Josse J, Husson F. FactoMineR: an R package for multivariate analysis. *Journal of*
461 *statistical software.* 2008;25(1):1-18.

462

463

464

465

466 **Supplementary Table S1: NEMP association results for each phenotype and PC in the gene SMART study.**


467 Output file is a compilation of multiple association results and is shown in Plink format. An additional “trait”
468 column has been added to illustrate which association test the results are from.

469


470

471 **Supplementary Fig 1: Summary figure of composite trait building with a PCA method.** The traits shown are
472 individual colours and contribute different amounts to each principal component from the analysis. Then each PC
473 will correspond to each participant that contributes to the original traits. Therefore association of a PC is equal to
474 association of the contribution to each PC from the participants.


SNP hits for Mitochondrial variants



SNP hits from NEMP genes



Harvey et al Figure 2



Harvey et al Figure 3